Effects of tebentafusp injection: A Synthesis of Findings from 1 Studies

  1. Home
  2. Effects of tebentafusp injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of tebentafusp injection: A Synthesis of Findings from 1 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of tebentafusp injection: A Synthesis of Findings from 1 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

This study evaluated the orthostatic effects and safety of coadministering silodosin with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. The study found that coadministration of silodosin and maximum therapeutic doses of sildenafil or tadalafil did not cause clinically important orthostatic changes in blood pressure or heart rate, and no orthostatic symptoms were observed. 1

Benefits and Risks

Benefit Summary

Coadministration of silodosin and PDE-5 inhibitors may not cause clinically important orthostatic changes or symptoms in healthy men. 1

Risk Summary

Coadministration of silodosin and PDE-5 inhibitors may have a small effect on blood pressure and heart rate. 1

Comparison of Studies

Commonalities

This study is the only one that has evaluated the safety and efficacy of coadministering silodosin with PDE-5 inhibitors. Therefore, there are no commonalities with other studies.

Differences

This study is the only one that has evaluated the safety and efficacy of coadministering silodosin with PDE-5 inhibitors. Therefore, there are no differences from other studies.

Consistency and Contradictions of Results

This study is the only one that has evaluated the safety and efficacy of coadministering silodosin with PDE-5 inhibitors. Therefore, there are no consistencies or contradictions with other studies.

Implications for Real-Life Application

This study was conducted on healthy men, so it is important to exercise caution when generalizing the results to other populations. Also, coadministration of silodosin and PDE-5 inhibitors may have a small effect on blood pressure and heart rate, so it is important to consult a doctor. 1

Limitations of the Current Study

This study is a small study that was conducted on healthy men, so the results may not be generalizable to other populations. Also, the study period was short (21 days), so long-term safety is unknown.

Future Research Directions

Larger studies are needed to evaluate the long-term safety and efficacy of coadministering silodosin with PDE-5 inhibitors. Also, studies should be conducted on other populations, such as older adults and women. 1

Conclusion

This study suggests that coadministration of silodosin with PDE-5 inhibitors may not cause clinically important orthostatic changes or symptoms in healthy men. However, the study was small and long-term safety is unknown. If you are considering coadministering silodosin and PDE-5 inhibitors, it is important to consult with your doctor. 1

Keywords
Benefit Keywords
Safe coadministration
1
Risk Keywords
Mild adverse events
1
Literature analysis of 1 papers
Positive Content
1
Neutral Content
0
Negative Content
0
Article Type
1
0
0
0
1
1.

Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

Author: MacDiarmidScott A, HillLawrence A, VolinnWeining, HoelGary

Safe coadministration
Mild adverse events

Co-administration of silodosin with sildenafil or tadalafil did not cause clinically significant orthostatic changes in blood pressure or heart rate in healthy men. The study found no significant differences in orthostatic effects between the treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.